WO2012042197A2 - Low dose pharmaceutical composition - Google Patents

Low dose pharmaceutical composition Download PDF

Info

Publication number
WO2012042197A2
WO2012042197A2 PCT/GB2011/001395 GB2011001395W WO2012042197A2 WO 2012042197 A2 WO2012042197 A2 WO 2012042197A2 GB 2011001395 W GB2011001395 W GB 2011001395W WO 2012042197 A2 WO2012042197 A2 WO 2012042197A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
zanamivir
composition according
dose
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2011/001395
Other languages
French (fr)
Other versions
WO2012042197A3 (en
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2013119595/15A priority Critical patent/RU2013119595A/en
Priority to EP11767280.8A priority patent/EP2621485A2/en
Priority to US13/825,469 priority patent/US20130251790A1/en
Priority to MX2013003523A priority patent/MX2013003523A/en
Priority to BR112013006857A priority patent/BR112013006857A2/en
Priority to CN2011800464443A priority patent/CN103260615A/en
Priority to AU2011309944A priority patent/AU2011309944A1/en
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of WO2012042197A2 publication Critical patent/WO2012042197A2/en
Publication of WO2012042197A3 publication Critical patent/WO2012042197A3/en
Priority to ZA2013/02012A priority patent/ZA201302012B/en
Anticipated expiration legal-status Critical
Priority to US14/504,051 priority patent/US20150034087A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention relates to a novel low dose pharmaceutical composition comprising an antiviral drug.
  • the present invention also provides a process of preparing such pharmaceutical composition and its use in the treatment and/or prophylaxis of influenza.
  • Influenza is a common condition affecting all age groups. It occurs mainly during the winter season and causes significant morbidity and increased mortality. The elderly and those with pre-existing medical problems, such as heart disease and renal disease, are particularly at the risk of suffering this severe disease or developing such complications.
  • Neuraminidase inhibitors are a class of antiviral drugs specifically targeted at the influenza virus, which act by blocking the function of the viral neuraminidase protein, thereby preventing the virus from reproducing by budding method from the host cell.
  • Zanamivir is the first such neuraminidase inhibitor to be developed commercially, and is used in the treatment of and prophylaxis of both Influenza virus A as well as Influenza virus B.
  • the chemical name of zanamivir is 5(acetylamino)-4-[(aminoiminomethyl)- amino]-2, 6-anhydro-3, 4, 5-trideoxy-D-glycero-D-galactonon-2-enonic acid.
  • Zanamivir is a selective inhibitor of neuraminidase, an enzyme that cleaves sialic acid from host and viral cell surfaces and thereby facilitates the release of progeny virus from infected host cells. Zanamivir also prevents neuraminidase from cleaving sialic acid from the host cells by blocking the active site of neuraminidase. The resultant binding of viral hemagglutinin to the uncleaved sialic acid hinders release of nascent viruses from the host cell and thereby causes them to clump at the host cell surface, with a net reduction in the amount of active virus.
  • Zanamivir has been approved for treatment and prophylaxis of illness due to influenza A and B virus in adults and in pediatric patients. Zanamivir is administered by oral inhalation. This mode of administration delivers drug directly to the pulmonary site of the influenza infection and thereby minimizes its systemic exposure.
  • the recommended therapeutic dose of zanamivir for treatment of influenza in adults as well as pediatric patients is 10 mg twice daily for 5 days. Further, the recommended therapeutic dose of zanamivir for prophylaxis of influenza in adults and pediatric patients in a household setting is 10 mg twice daily for 10 days and the recommended therapeutic dose of zanamivir for prophylaxis of influenza in adults and pediatric patients in a community setting is 10 mg once daily for 28 days.
  • EP0764023 discloses administration of zanamivir by mouth via inhalation or insufflation.
  • JP2002241310 discloses locally applicable compositions in the form of nasal drops and inhalants containing influenza virus inhibitors such as zanamivir.
  • CN 101229122 discloses formulations of zanamivir in a nasal in-situ gel with advantages of improved concentration of zanamivir in respiratory tracts, long drug detention time, high bioavailability, improved patient compliance, and no nasal ciliary toxicity.
  • CNl 01773468 discloses nasal nanoscale suspensions of zanamivir with advantages of low dosage, long mucous membrane detention time, and good curative effects.
  • CN101773491 discloses a zanamivir inhalation solution.
  • Various formulations that are disclosed and that are available in the market contain a dose of 5 mg of zanamivir for twice a day administration.
  • no composition is yet available which includes low dose zanamivir, wherein the total daily dose of zanamivir is less than the conventionally administered daily dose of at least about 10 mg of zanamivir, and which is still effective for the prophylaxis and/or treatment of influenza.
  • compositions comprising a low dose of zanamivir, wherein the total daily dose of zanamivir is less than the conventionally administered daily dose of zanamivir, and which also does not require the use of any specific bioenhancer and which can release the drug in a desired manner and in a quantity sufficient to alleviate desired pathological conditions without causing or at least minimizing dose related toxicity, and can be prepared in an easy and cost-effective manner.
  • An object of the present invention is to provide a novel low dose pharmaceutical composition comprising zanamivir along with one or more pharmaceutically acceptable excipient(s).
  • Another object of the present invention is to provide a novel low dose pharmaceutical composition comprising zanamivir wherein the total daily dose of zanamivir is less than the conventionally administered daily dose of at least about 10 mg of zanamivir.
  • Yet another object of the present invention is to provide a process for preparing the pharmaceutical composition comprising a low dose of zanamivir for administration in the treatment or prophylaxis of influenza.
  • a further object of the present invention is to provide a method for treatment and/or prophylaxis of influenza which comprises administering a pharmaceutical composition comprising a low dose of zanamivir.
  • a pharmaceutical composition comprising a low dose of zanamivir.
  • a pharmaceutical composition comprising a low dose zanamivir for use in the treatment and/or prophylaxis of influenza.
  • a method of treatment and/or prophylaxis of influenza which comprises administering a dry powder inhaler composition comprising a low dose zanamavir.
  • Zanamivir has been administered conventionally by oral inhalation as 5 mg twice a day for the treatment and/or prophylaxis of illness due to influenza A as well as influenza B.
  • the inventors of this invention have made an effort to provide a lower dose of zanamivir, which lower dose can also be effectively administered for the treatment and/or prevention of influenza. Furthermore, the low dose compositions of the present invention have improved bioavailability, and are easy to formulate. Preferably, the compositions of the present invention do not require the use of any specific bioenhancer or the like.
  • 'low dose' refers to a therapeutically effective dose of zanamivir, which dose is less than the usual or the conventional dose required to produce the therapeutic effect.
  • Zanamivir is used in broad sense to include not only “Zanamivir” per se but also their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable esters, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable complexes etc.
  • the present invention provides novel low dose pharmaceutical compositions comprising zanamivir or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof, along with one or more pharmaceutically acceptable excipient(s).
  • a pharmaceutical composition comprising zanamivir with one or more pharmaceutically acceptable excipients wherein the total daily dose of the zanamivir is less than 10 mg.
  • the pharmaceutical composition, according to the present invention may be administered at least once a day.
  • the pharmaceutical composition is administered once a day or twice a day in a dose which is less than the conventionally administered dose, which is about 5 mg of zanamivir twice a day.
  • the present invention provides a novel low dose pharmaceutical composition
  • a novel low dose pharmaceutical composition comprising zanamivir wherein the dose of the zanamivir is in a range of 3 mg to 8 mg, for administration at least once a day, and wherein the total daily dose of zanamivir is less than the conventionally administered daily dose of at least about 10 mg of zanamivir. Therefore, the pharmaceutical composition of the present invention may provide a dose of ⁇ 10 mg zanamivir for once a day administration or a dose of ⁇ 5 mg for twice a day administration.
  • the pharmaceutical composition of the present invention may provide a dose of ⁇ 8 mg, or a dose of ⁇ 7 mg, or a dose of ⁇ 6 mg, or a dose of ⁇ 5 mg, or a dose of ⁇ 4 mg, or a dose of ⁇ 3 mg.
  • the pharmaceutical composition, according to the present invention may exhibit bioavailability to an extent to produce the desired pharmacological effects along with reduced side effects after dosing in a subject.
  • the pharmaceutical composition may be used for the treatment and/or prophylaxis of viral diseases caused by orthomyxoviruses and paramyxoviruses such as, but not limited to, influenza A and B, parainfluenza, mumps, and Newcastle disease, fowl plaque and Sendai virus.
  • orthomyxoviruses and paramyxoviruses such as, but not limited to, influenza A and B, parainfluenza, mumps, and Newcastle disease, fowl plaque and Sendai virus.
  • compositions of the present invention may be administered by any suitable methods used for delivery of the drugs to the respiratory tract.
  • the composition of the present invention may thus be administered as metered dose inhalers (MDI), dry powder inhalers (DPI), solution or suspension for nebuliser, nasal spray, nasal drops, insufflation powders.
  • MDI metered dose inhalers
  • DPI dry powder inhalers
  • solution or suspension for nebuliser nasal spray, nasal drops, insufflation powders.
  • the various dosage forms according to the present invention may comprise carriers/excipients suitable for formulating the same.
  • the pharmaceutical composition of the present invention may be administered by a dry powder inhaler (DPI).
  • DPI dry powder inhaler
  • the pharmaceutically acceptable excipients suitable for dry powder inhalation according to the present invention may be selected from suitable carriers which comprise, but are not limited to, sugars such as glucose, saccharose, lactose and fructose, starches or starch derivatives, oligosaccharides such as dextrins, cyclodextrins and their derivatives, polyvinylpyrrolidone, alginic acid, tylose, silicic acid, cellulose, cellulose derivatives (for example cellulose ether), sugar alcohols such as mannitol or sorbitol, calcium carbonate, calcium phosphate, lactose, lactitol, dextrates, dextrose, maltodextrin, saccharides including monosaccharides, disaccharides, polysaccharides; sugar alcohols such as arabinose, ribose, mannose, sucrose, trehalose, maltose and dextran.
  • suitable carriers comprise, but are not limited to,
  • the powder for inhalation intended to be used for DPI may either be encapsulated in capsules of gelatin or hydroxypropyl methylcellulose or in blisters or alternatively, the dry powder may be contained as a reservoir either in a single dose or multi-dose dry powder inhalation device.
  • the pharmaceutical composition of the present invention intended to be used as a DPI may be administered via RevolizerTM.
  • the RevolizerTM is an inhalation device for inhalation of a medicament from a pierceable capsule, which inhaler comprises a housing for receiving a medicament capsule; closure means for closing the housing, said closure means being moveable relative to the housing; piercing means suitable for piercing a medicament capsule; wherein movement of the closure means relative to the housing causes movement of the piercing means.
  • the RevolizerTM inhalation device may also comprise linking means connected to both the closure means and the piercing means, wherein movement of the closure means causes movement of the linking means so as to move the piercing means.
  • movement of the closure means causes movement or rotation of the linking means.
  • piercing or perforation of a capsule received in the housing occurs as a consequence of merely closing the housing subsequent to having placed a medicament- containing capsule therein.
  • the user is not required to perform any additional actions prior to inhalation of medicament from the inhaler device, other than inserting a capsule and closing the device.
  • the inclusion of one more vents enables the patient to inhale more easily, because of a reduced resistance to air flow. In other words, the perceived resistance to inhalation experienced by the user is lower.
  • the RevolizerTM inhalation device will comprise at least one main primary air inlet through which air is initially drawn from the atmosphere into the device. Likewise, the device will also comprise a final air outlet through which inhaled air exits the device and enters the patient's mouth. Between this initial air inlet and final air outlet, the device will define a passageway through the body of the device through which air flows. The passageway is referred to herein as the inhalation passage.
  • the inhalation passage of the RevolizerTM inhalation device comprises one or more vents, which it will be understood are essentially auxiliary air inlets. The vents may be positioned at one or more points along the inhalation passage and are essentially small openings in the wall of the inhalation passage, which serve to connect air in the inhalation passage with air external to the passage.
  • vents which suitably oppose each other, are employed, although one vent, or more than two vents may be employed if desired.
  • the vents can be of any suitable shape and size, although they are preferably crescent-shaped.
  • the housing preferably comprises means to hold a medicament capsule; said holding means preferably comprising a chamber having one or more air inlets and air outlet(s).
  • the air inlet of the chamber may constitute the primary air inlet of the device, or the primary air inlet of the device may be provided separately on the device, for example elsewhere on the housing.
  • the or each air inlet and outlet are preferably provided at opposing ends of the chamber.
  • the or each air inlet is positioned in, or near to, the base of the medicament holder. They may, for example, be provided on the walls of the chamber, for example on the lower walls.
  • the flow of air via the or each inlet may be at a tangent to, or at an angle offset from, the longitudinal axis of the chamber.
  • a single air inlet may be used.
  • two or more inlets may be used.
  • two air inlets may be provided at or near the bottom of the holder. Preferably, they are provided in the lower vertical walls of the chamber.
  • two inlets may be provided substantially opposite to one another in the lower walls. These inlets may, if desired, be offset from one another; for example in a tangential arrangement.
  • the closure means preferably comprises a mouthpiece. That is to say, the closure means is preferably such that it includes means by or via which medicament may be inhaled from the device by the user.
  • An inhaler mouthpiece is preferably pivotably attached to the housing.
  • the air outlet of the medicament chamber is suitably positioned so as to connect or coincide with the mouthpiece in its fully closed position.
  • the mouthpiece may suitably comprise means to receive air from an outlet of the medicament chamber, such that when the mouthpiece is closed the means for receiving air is connected with, or cooperates with, the outlet.
  • the means e.g. a tube which may be cylindrical or oval shaped in cross section
  • the end which connects with the outlet of the medicament chamber comprises the vents, preferably two opposing crescent-shaped vents positioned at either side.
  • the arrangement is preferably such that the vents are in close proximity to the outlet of the medicament chamber.
  • the outlet of the said means may constitute the final air outlet of the inhaler device.
  • the positioning, in particular the angle, of the vents is such that in use the direction of airflow through the vents is in the same general direction as the direction of the main inhalation airflow through the inhalation passage.
  • the vents are typically formed as a hole or opening through the thickness of one or more walls of the inhalation passage. Where the wall thickness is such that an axis through the vent can be defined, the axis of the vent is preferably at an angle of less than 90 degrees, more preferably 45 degrees or less, relative to the direction of the main inhalation airflow through the inhalation passage. That is to say, the flow of air through the vents into the inhalation passage is preferably not perpendicular to, or against, the main inhalation flow, but flows in the same general direction.
  • the RevolizerTM inhalation device comprises a holder for a medicament, which holder comprises a chamber suitable for receiving a medicament capsule; and means for generating turbulence in a fluid flow through the chamber such that, in use, the turbulent fluid flow causes vibration of a capsule received by the chamber so as to assist in releasing medicament contained within the capsule. Maximizing the turbulence in the chamber enhances drug dispersion and delivery.
  • the means for generating turbulence preferably also holds, or partially holds, a medicament capsule within the holder.
  • the means for generating turbulence holds one end of a medicament capsule.
  • the capsule is held loosely (either completely, partially or at one end), which means that any significant movement of the capsule is prevented but the capsule is still enabled to make small vibratory movements within the chamber.
  • the means for generating turbulence may be any suitable means but preferably comprises one or more projections or flow barriers extending from the inner walls of the chamber.
  • the means for generating turbulence extend substantially the entire length of the chamber - that is, substantially from top to bottom. Increasing the height of the means for generating turbulence results in reduced retention of medicament in the chamber, and also reduced leakage of medicament from around the top of the chamber.
  • the pharmaceutical composition of the present invention may be administered by a metered dose inhaler (MDI).
  • MDI metered dose inhaler
  • the metered dose inhalers may comprise one or more pharmaceutically acceptable excipients such as hydrofluoroalkane (HFC/HFA) propellants, co-solvents, bulking agents, non volatile component, buffers/pH adjusting agents, surface active agents, preservatives, complexing agents, or combinations thereof.
  • HFC/HFA hydrofluoroalkane
  • Propellants are those which, when mixed with the cosolvent(s), form a homogeneous propellant system in which a therapeutically effective amount of the active can be dissolved.
  • the hydrofluoroalkane HFC/HFA propellant must be toxicologically safe and must have a vapor pressure which is suitable to enable the medicament to be administered via a pressurized MDI.
  • the HFC/HFA propellants may comprise, but are not limited to, one or more of 1,1, 1,2-tetrafluoroethane (HFC-134(a)) and 1,1,1,2,3,3,3,- heptafluoropropane (HFC-227), HFC-32 (difluoromethane), HFC-143(a) (1,1,1-trifluoroethane), HFC-134 (1,1,2,2-tetrafluoroethane), and HFC-152a (1,1- difluoroethane) and such other propellants which may be known to the person a skilled in the art.
  • HFC-134(a) 1,1,1,2-tetrafluoroethane
  • HFC-227 1,1,1,2,3,3,3,3,- heptafluoropropane
  • HFC-32 difluoromethane
  • HFC-143(a) (1,1,1-trifluoroethane
  • HFC-134 1,1,2,2-tetrafluor
  • Co-solvent is any solvent which may be volatile or non-volatile, which is miscible in the formulation in the amount desired and which, when added provides a formulation in which the medicament can be dissolved or suspended.
  • the function of the cosolvent is to increase the solubility of the medicament and the excipients in the formulation.
  • the volatile and non-volatile co-solvent may comprise one or more of, C 2- C 6 aliphatic alcohols, such as but not limited to, ethyl alcohol and isopropyl alcohol; glycols such as but not limited to, propylene glycol, polyethylene glycols, polypropylene glycols, glycol ethers, and block copolymers of oxyethylene and oxypropylene; and other substances, such as but not limited to, polyoxyethylene alcohols, and polyoxyethylene fatty acid esters; hydrocarbons such as but not limited to, n-propane, n-butane, isobutane, n-pentane, iso-pentane, neo-pentane, and n-hexane; and ethers such as but not limited to, diethyl ether, monosaccharides such as but not limited to, glucose, arabinose; disaccharides such as lactose, maltose;
  • Suitable buffers or pH adjusting agents may be employed in the MDI formulation of the present invention.
  • the buffer or the pH adjusting agent may comprise one or more of organic or inorganic acids such as but not limited to, citric acid, ascorbic acid, hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid.
  • Suitable preservatives may be employed in the MDI formulation of the present invention to protect the formulation from contamination with pathogenic bacteria.
  • the preservative may comprise, but not limited to, one or more of benzalkonium chloride, benzoic acid, benzoates such as sodium benzoate and such other preservatives which may be known to the person skilled in the art.
  • Suitable complexing agents may also be employed in the MDI formulation of the present invention which are capable of forming complex bonds.
  • the complexing agent may comprise one or more of, but not limited to sodium EDTA or disodium EDTA.
  • Suitable surfactants may also be employed in the MDI formulation of the present invention which serve to stabilize the solution formulation and improve the performance of valve systems of the metered dose inhaler.
  • the surfactant may comprise one or more ionic and/or non-ionic surfactant, but not limited to, oleic acid, sorbitan trioleate, lecithin, isopropylmyristate, tyloxapol, polysorbates such as polysorbate 80, vitamin E-TPGS, and macrogol hydroxystearates such as macrogol-15-hydroxystearate.
  • the powder for inhalation intended to be used for DPI may be suspended in a suitable vehicle and packaged in a container along with suitable propellants or mixtures thereof to form a composition suitable for administration by MDI.
  • Suitable vehicles which may be used in the pharmaceutical composition of the invention may comprise, but are not limited to, polar solvents, such as compounds that contain hydroxyl groups or other polar groups.
  • solvents may include water or alcohols, such as ethanol, isopropanol, and glycols including propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol and polyoxyethylene alcohols.
  • the pharmaceutical composition of the present invention may be administered by nebulization.
  • the pharmaceutical composition to be administered by a nebulizer may comprise suitable excipients such as, but not limited to, tonicity agents, surfactants or wetting agents, buffers/pH regulators, chelating agents in a suitable vehicle such as water.
  • suitable excipients such as, but not limited to, tonicity agents, surfactants or wetting agents, buffers/pH regulators, chelating agents in a suitable vehicle such as water.
  • Suitable surfactants or wetting agents may also be used in the pharmaceutical compositions of the present invention.
  • the surfactants may comprise one or more of, but not limited to polysorbates such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 65, polysorbate 85, sorbitan.
  • fatty acid esters such as Span 20, Span 40, Span 60, Span 80, Span 120; sodium lauryl sulfate; polyethoxylated castor oil; polyethoxylated hydrogenated castor oil, sodium dodecyl sulfate (sodium lauryl sulfate), lauryl dimethyl amine oxide, docusate sodium, cetyl trimethyl ammonium bromide (CTAB), polyethoxylated alcohols, polyoxyethylene sorbitan, octoxynol, N, N-dimethyldodecylamine-N-oxide, Hexadecyltrimethyl- ammonium bromide, polyoxyl 10 lauryl ether, Brij, bile salts (sodium deoxycholate, sodium cholate), polyoxyl castor oil, nonylphenol ethoxylate, cyclodextrins, lecithin, methylbenzethonium chloride, carboxylates,
  • Tonicity-adjusting agents comprise, but are not limited to, sodium chloride, potassium chloride, zinc chloride, calcium chloride and mixtures thereof.
  • Other isotonicity-adjusting agents may also include, but are not limited to, mannitol, glycerol, and dextrose and mixtures thereof.
  • the pH may be adjusted by the addition of pharmacologically acceptable acids.
  • Pharmacologically acceptable inorganic acids or organic acids may be used for this purpose.
  • preferred inorganic acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and phosphoric acid.
  • particularly suitable organic acids are selected from the group consisting of ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and propionic acid.
  • Complexing agents according to the present invention may comprise, but are not limited to, editic acid (EDTA) or one of the known salts thereof, e.g. sodium EDTA or disodium EDTA dihydrate (sodium edetate).
  • An anti-microbial preservative agent may be added for multi-dose packages.
  • the pharmaceutical composition according to the present invention is administered using dosage forms suitable for delivery of drugs to the respiratory tract.
  • dosage forms suitable for delivery of drugs to the respiratory tract.
  • other dosage forms such as parentral dosage forms may also be envisaged under the ambit of the invention.
  • the present invention also provides a process to manufacture compositions according to the present invention.
  • the present invention provides a process of preparing a dry powder inhalation formulation which process comprises admixing of a pharmaceutically acceptable carrier or excipient with the actives and providing the formulation as a dry powder inhaler.
  • the present invention further provides a method for treatment and/or prophylaxis of influenza which comprises administering a pharmaceutical composition according to the present invention comprising a low dose of zanamivir.
  • composition may further comprise one or more active in particular antibiotics, anti-bacterial and other anti-viral agents such as those used to treat respiratory infections.
  • influenza viruses such as but not limited to, amantadine, rimantadine, acyclovir, azidothymidine, vidarabine, ribavirin, dapsone, chloramphenicol, neomycin, cefaclor, cefadroxil, cephalexin, erythromycin, clindamycin, lincomycin, amoxicillin, ampicillin, carbenicillin, methicillin, nafcillin, penicillin, polymyxin, tetracycline, amphotericin-b, candicidin, lucensomycin, mepartricin, natamycin, nystatin, griseofulvin, oligomycins, neomycin tubercidin, picloxacillin, penicllins, sulfonamides, cephalosporins, quinolones, or their pharmaceutically acceptable salts, solvates, tautomers, derivative
  • Zanamivir was sifted with fine lactose.
  • step (2) The mixture obtained in step (1) was co-sifted with coarse lactose.
  • step (2) The mixture obtained in step (2) was blended and filled into capsules.
  • Zanamivir was sifted with fine lactose.
  • step (2) The mixture obtained in step (1) was co-sifted with coarse lactose.
  • step (2) The mixture obtained in step (2) was blended and filled into capsules.
  • Figure 1 is a cross-sectional view of the inhalation device, with piercing means in a fully retracted position and the inhaler mouthpiece in a fully opened position.
  • Figure 2 is a cross-sectional view of the inhalation device, with piercing means in a fully extended piercing position and the inhaler mouthpiece in a partially open/partially closed position, and illustrates a preferred position of the vents.
  • Figure 3 is a cross-sectional view of the inhalation device, with piercing means in a fully retracted position and the inhaler mouthpiece in a fully closed position.
  • Figure 4 is a perspective view of the exterior of the inhalation device with the mouthpiece in the fully closed position.
  • Figure 5 is a plan view of a side of the inhalation device with the mouthpiece in the fully closed position.
  • Figure 6 is a plan view of the other side (with respect to Figure 5) of the inhalation device with the mouthpiece in the fully closed position.
  • Figure 7 is a plan view of the rear of the inhalation device with the mouthpiece in the fully closed position.
  • Figure 8 is a plan view of the front of the inhalation device with the mouthpiece in the fully closed position.
  • Figure 9 is a top end view of the inhalation device with the mouthpiece in the fully closed position, viewed from the mouthpiece end.
  • Figure 10 is a bottom end view of the inhalation device with the mouthpiece in the fully closed position, viewed from the lower body end.
  • Figure 11 is a perspective view of a holder for a dry powder medicament capsule.
  • Figure 12 is an end view of the medicament capsule holder, viewed from the air outlet end.
  • Figure 13 is an end view of the medicament capsule holder viewed from the air inlet end.
  • Figure 14 is a front view of the medicament capsule holder.
  • Figure 15 is a side view of the medicament capsule holder.
  • Figure 16 is a rear view of the medicament capsule holder.
  • Figure 17 is a side view of the medicament capsule holder.
  • Figure 18 is a top end view of a preferred inhalation device with the mouthpiece in the fully closed position, viewed from the mouthpiece end. It illustrates the position of the vents.
  • Figure 19 is a cross-section of a preferred inhalation device illustrating projections ( 16) of increased height compared to Figure 11.
  • Figure 20 is a cross-section of a preferred inhalation device and shows a preferred position of the vents.
  • the RevolizerTM inhalation device comprises a lower body (1) having a medicament or capsule holder (2) to hold the capsule or similar suitable medicament receptacle, and a mouthpiece (3) attached to the lower body (1) by a pivot (30) about which the mouthpiece (3) is rotatable.
  • the medicament or capsule holder (2) comprises a chamber (14) to receive a capsule, an air inlet (1 1), an air outlet (12), and means for generating turbulence (16).
  • the means for generating turbulence (16) may comprise one or more projection(s), as shown in Figures 1 1 and 12.
  • the projections (16) extend to substantially the top of medicament chamber (14) so that they align with the upper rim of the chamber (14), as illustrated in Figure 19.
  • the means for generating turbulence (16) have a dual function: they both hold a capsule (10) received within the chamber (14), and generate turbulence in fluid flow through the chamber (14) and around a capsule (10) received therein.
  • the capsule holder (2) is preferably adapted to receive one or more piercing pins (7) that are moveable between a retracted position in a piercing pin holder (6), shown in Figures 1 and 3, and an extended piercing position, shown in Figure 2.
  • the piercing pins (7) are operated by a link (5) that enables the linear movement of the piercing pin (7) to pierce the capsule or similar suitable medicament receptacle (10) and retract back.
  • guide means (20) extend from the openings (18) in a side wall of the chamber (2).
  • the guide means (20) are positioned so as to guide the movement of the piercing pins (7) between fully extended and fully retracted positions.
  • the guide means (20) can be best appreciated from Figures 11 to 17.
  • the mouthpiece (3) pivots laterally to the lower body (1) so as to rotate about an axis and thereby open and close the outlet (12) of the capsule holder (2).
  • Figure 2 illustrates the preferred position of the vents (70, the vents themselves are not shown in the drawing). Two crescent-shaped vents are positioned opposing each other on either side of a mesh (9). Figure 2 also illustrates the primary air inlet (71) on the base of the lower body or housing (1), and the final air outlet (72) on mouthpiece (3). When the device is in the closed position (as in Figure 3), the device defines an inhalation passage extending through the device between inlet (71) and outlet (72).
  • Figure 18 illustrates a preferred position of the vents (70) relative to mesh (9). The exact positioning can be appreciated with reference to Figure 20, which shows the position of vents (70) relative to the mouthpiece (3) and lower body (1).
  • the mouthpiece (3) is opened, thereby retracting the piercing pins (7), and a capsule or similar suitable medicament receptacle (10) is placed into the chamber (14).
  • the projections (16) loosely hold the capsule (10) within the chamber (14).
  • the piercing pins (7) pierce the capsule (10) in the capsule holder (2) as shown in Figure 2.
  • the piercing pins retract from the medicament holder (2).
  • the projections (16) generate turbulence in the air flow through the chamber (14).
  • Turbulence in the air flowing around the capsule (10) causes vibration of the capsule (10) within the chamber (14), and this vibration enhances the dispersion of medicament contained within the capsule (10). Accordingly, less forceful inhalation by the user is required to liberate a full dose of medicament from the capsule (10).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition comprising a low dose of zanamivir and a process for preparing the pharmaceutical composition comprising a low dose of zanamivir. The pharmaceutical composition comprising a low dose zanamivir may be used in the treatment and/or prophylaxis of influenza. The present invention also provides a method of treatment and/or prophylaxis of influenza which comprises administering a dry powder inhaler composition comprising a low dose zanamavir. The pharmaceutical composition of the present invention comprises zanamivir and one or more pharmaceutically acceptable excipients, wherein the total daily dose of the zanamivir is less than 10 mg, preferably for administration at least once a day, and preferably wherein the composition delivers from 3 mg to 8 mg of zanamivir per administered dose.

Description

LOW DOSE PHARMACEUTICAL COMPOSITION
FIELD OF INVENTION:
The present invention relates to a novel low dose pharmaceutical composition comprising an antiviral drug. The present invention also provides a process of preparing such pharmaceutical composition and its use in the treatment and/or prophylaxis of influenza.
BACKGROUND OF INVENTION:
Influenza is a common condition affecting all age groups. It occurs mainly during the winter season and causes significant morbidity and increased mortality. The elderly and those with pre-existing medical problems, such as heart disease and renal disease, are particularly at the risk of suffering this severe disease or developing such complications.
Neuraminidase inhibitors are a class of antiviral drugs specifically targeted at the influenza virus, which act by blocking the function of the viral neuraminidase protein, thereby preventing the virus from reproducing by budding method from the host cell.
Zanamivir is the first such neuraminidase inhibitor to be developed commercially, and is used in the treatment of and prophylaxis of both Influenza virus A as well as Influenza virus B. The chemical name of zanamivir is 5(acetylamino)-4-[(aminoiminomethyl)- amino]-2, 6-anhydro-3, 4, 5-trideoxy-D-glycero-D-galactonon-2-enonic acid.
Figure imgf000002_0001
Zanamivir is a selective inhibitor of neuraminidase, an enzyme that cleaves sialic acid from host and viral cell surfaces and thereby facilitates the release of progeny virus from infected host cells. Zanamivir also prevents neuraminidase from cleaving sialic acid from the host cells by blocking the active site of neuraminidase. The resultant binding of viral hemagglutinin to the uncleaved sialic acid hinders release of nascent viruses from the host cell and thereby causes them to clump at the host cell surface, with a net reduction in the amount of active virus.
Zanamivir has been approved for treatment and prophylaxis of illness due to influenza A and B virus in adults and in pediatric patients. Zanamivir is administered by oral inhalation. This mode of administration delivers drug directly to the pulmonary site of the influenza infection and thereby minimizes its systemic exposure.
The recommended therapeutic dose of zanamivir for treatment of influenza in adults as well as pediatric patients is 10 mg twice daily for 5 days. Further, the recommended therapeutic dose of zanamivir for prophylaxis of influenza in adults and pediatric patients in a household setting is 10 mg twice daily for 10 days and the recommended therapeutic dose of zanamivir for prophylaxis of influenza in adults and pediatric patients in a community setting is 10 mg once daily for 28 days.
EP0764023 discloses administration of zanamivir by mouth via inhalation or insufflation.
JP2002241310 discloses locally applicable compositions in the form of nasal drops and inhalants containing influenza virus inhibitors such as zanamivir.
CN 101229122 discloses formulations of zanamivir in a nasal in-situ gel with advantages of improved concentration of zanamivir in respiratory tracts, long drug detention time, high bioavailability, improved patient compliance, and no nasal ciliary toxicity.
CNl 01773468 discloses nasal nanoscale suspensions of zanamivir with advantages of low dosage, long mucous membrane detention time, and good curative effects.
CN101773491 discloses a zanamivir inhalation solution. Various formulations that are disclosed and that are available in the market contain a dose of 5 mg of zanamivir for twice a day administration. However, no composition is yet available which includes low dose zanamivir, wherein the total daily dose of zanamivir is less than the conventionally administered daily dose of at least about 10 mg of zanamivir, and which is still effective for the prophylaxis and/or treatment of influenza.
Hence, there still exists a need to develop pharmaceutical compositions comprising a low dose of zanamivir, wherein the total daily dose of zanamivir is less than the conventionally administered daily dose of zanamivir, and which also does not require the use of any specific bioenhancer and which can release the drug in a desired manner and in a quantity sufficient to alleviate desired pathological conditions without causing or at least minimizing dose related toxicity, and can be prepared in an easy and cost-effective manner.
OBJECT OF THE INVENTION:
An object of the present invention is to provide a novel low dose pharmaceutical composition comprising zanamivir along with one or more pharmaceutically acceptable excipient(s).
Another object of the present invention is to provide a novel low dose pharmaceutical composition comprising zanamivir wherein the total daily dose of zanamivir is less than the conventionally administered daily dose of at least about 10 mg of zanamivir.
Yet another object of the present invention is to provide a process for preparing the pharmaceutical composition comprising a low dose of zanamivir for administration in the treatment or prophylaxis of influenza.
A further object of the present invention is to provide a method for treatment and/or prophylaxis of influenza which comprises administering a pharmaceutical composition comprising a low dose of zanamivir. SUMMARY OF THE INVENTION:
According to one aspect of the present invention, there is provided a pharmaceutical composition comprising a low dose of zanamivir.
According to another aspect of the present invention there is provided a process for preparing the pharmaceutical composition comprising a low dose of zanamivir.
According to yet another aspect of the present invention there is provided a pharmaceutical composition comprising a low dose zanamivir for use in the treatment and/or prophylaxis of influenza.
According to a further aspect of the present invention there is provided a method of treatment and/or prophylaxis of influenza which comprises administering a dry powder inhaler composition comprising a low dose zanamavir.
DETAILED DESCRIPTION OF THE INVENTION:
Zanamivir has been administered conventionally by oral inhalation as 5 mg twice a day for the treatment and/or prophylaxis of illness due to influenza A as well as influenza B.
The inventors of this invention have made an effort to provide a lower dose of zanamivir, which lower dose can also be effectively administered for the treatment and/or prevention of influenza. Furthermore, the low dose compositions of the present invention have improved bioavailability, and are easy to formulate. Preferably, the compositions of the present invention do not require the use of any specific bioenhancer or the like.
The term 'low dose' as used herein refers to a therapeutically effective dose of zanamivir, which dose is less than the usual or the conventional dose required to produce the therapeutic effect. The term "Zanamivir" is used in broad sense to include not only "Zanamivir" per se but also their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable esters, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs, pharmaceutically acceptable prodrugs, pharmaceutically acceptable complexes etc.
The present invention provides novel low dose pharmaceutical compositions comprising zanamivir or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof, along with one or more pharmaceutically acceptable excipient(s).
According to one aspect of the present invention, there is provided a pharmaceutical composition comprising zanamivir with one or more pharmaceutically acceptable excipients wherein the total daily dose of the zanamivir is less than 10 mg.
The pharmaceutical composition, according to the present invention may be administered at least once a day. Preferably the pharmaceutical composition is administered once a day or twice a day in a dose which is less than the conventionally administered dose, which is about 5 mg of zanamivir twice a day.
According to an embodiment of the present invention provides a novel low dose pharmaceutical composition comprising zanamivir wherein the dose of the zanamivir is in a range of 3 mg to 8 mg, for administration at least once a day, and wherein the total daily dose of zanamivir is less than the conventionally administered daily dose of at least about 10 mg of zanamivir. Therefore, the pharmaceutical composition of the present invention may provide a dose of <10 mg zanamivir for once a day administration or a dose of <5 mg for twice a day administration. The pharmaceutical composition of the present invention may provide a dose of < 8 mg, or a dose of < 7 mg, or a dose of < 6 mg, or a dose of < 5 mg, or a dose of < 4 mg, or a dose of < 3 mg. The pharmaceutical composition, according to the present invention, may exhibit bioavailability to an extent to produce the desired pharmacological effects along with reduced side effects after dosing in a subject.
The pharmaceutical composition, according to the present invention, may be used for the treatment and/or prophylaxis of viral diseases caused by orthomyxoviruses and paramyxoviruses such as, but not limited to, influenza A and B, parainfluenza, mumps, and Newcastle disease, fowl plaque and Sendai virus.
The pharmaceutical composition, of the present invention, may be administered by any suitable methods used for delivery of the drugs to the respiratory tract. The composition of the present invention may thus be administered as metered dose inhalers (MDI), dry powder inhalers (DPI), solution or suspension for nebuliser, nasal spray, nasal drops, insufflation powders.
The various dosage forms according to the present invention may comprise carriers/excipients suitable for formulating the same.
According to one embodiment the pharmaceutical composition of the present invention may be administered by a dry powder inhaler (DPI).
The pharmaceutically acceptable excipients suitable for dry powder inhalation according to the present invention, may be selected from suitable carriers which comprise, but are not limited to, sugars such as glucose, saccharose, lactose and fructose, starches or starch derivatives, oligosaccharides such as dextrins, cyclodextrins and their derivatives, polyvinylpyrrolidone, alginic acid, tylose, silicic acid, cellulose, cellulose derivatives (for example cellulose ether), sugar alcohols such as mannitol or sorbitol, calcium carbonate, calcium phosphate, lactose, lactitol, dextrates, dextrose, maltodextrin, saccharides including monosaccharides, disaccharides, polysaccharides; sugar alcohols such as arabinose, ribose, mannose, sucrose, trehalose, maltose and dextran. The pharmaceutical, composition according to the present invention, may be included in suitable containers provided with means enabling the application of the contained formulation to the respiratory tract.
The powder for inhalation intended to be used for DPI may either be encapsulated in capsules of gelatin or hydroxypropyl methylcellulose or in blisters or alternatively, the dry powder may be contained as a reservoir either in a single dose or multi-dose dry powder inhalation device.
According to one embodiment of the present invention, the pharmaceutical composition of the present invention, intended to be used as a DPI may be administered via Revolizer™.
Preferred embodiments of our Revolizer™ are described in WO 2006/051300 and WO 2007/144659 and online at revolizer.com. In its broadest aspect, the Revolizer™ is an inhalation device for inhalation of a medicament from a pierceable capsule, which inhaler comprises a housing for receiving a medicament capsule; closure means for closing the housing, said closure means being moveable relative to the housing; piercing means suitable for piercing a medicament capsule; wherein movement of the closure means relative to the housing causes movement of the piercing means. The Revolizer™ inhalation device may also comprise linking means connected to both the closure means and the piercing means, wherein movement of the closure means causes movement of the linking means so as to move the piercing means. Preferably, movement of the closure means causes movement or rotation of the linking means.
Thus, in use, piercing or perforation of a capsule received in the housing occurs as a consequence of merely closing the housing subsequent to having placed a medicament- containing capsule therein. The user is not required to perform any additional actions prior to inhalation of medicament from the inhaler device, other than inserting a capsule and closing the device. We have found that the inclusion of one more vents enables the patient to inhale more easily, because of a reduced resistance to air flow. In other words, the perceived resistance to inhalation experienced by the user is lower.
It will be appreciated that the Revolizer™ inhalation device will comprise at least one main primary air inlet through which air is initially drawn from the atmosphere into the device. Likewise, the device will also comprise a final air outlet through which inhaled air exits the device and enters the patient's mouth. Between this initial air inlet and final air outlet, the device will define a passageway through the body of the device through which air flows. The passageway is referred to herein as the inhalation passage. In preferred embodiments, the inhalation passage of the Revolizer™ inhalation device comprises one or more vents, which it will be understood are essentially auxiliary air inlets. The vents may be positioned at one or more points along the inhalation passage and are essentially small openings in the wall of the inhalation passage, which serve to connect air in the inhalation passage with air external to the passage.
Preferably, two vents, which suitably oppose each other, are employed, although one vent, or more than two vents may be employed if desired. The vents can be of any suitable shape and size, although they are preferably crescent-shaped.
It is preferred to position these vents upstream of the medicament capsule, relative to the flow of air through the inhalation passage.
The housing preferably comprises means to hold a medicament capsule; said holding means preferably comprising a chamber having one or more air inlets and air outlet(s). The air inlet of the chamber may constitute the primary air inlet of the device, or the primary air inlet of the device may be provided separately on the device, for example elsewhere on the housing. The or each air inlet and outlet are preferably provided at opposing ends of the chamber. In a preferred embodiment, the or each air inlet is positioned in, or near to, the base of the medicament holder. They may, for example, be provided on the walls of the chamber, for example on the lower walls. The flow of air via the or each inlet may be at a tangent to, or at an angle offset from, the longitudinal axis of the chamber. In one embodiment, a single air inlet may be used. Alternatively, two or more inlets may be used. For example, two air inlets may be provided at or near the bottom of the holder. Preferably, they are provided in the lower vertical walls of the chamber. For example, two inlets may be provided substantially opposite to one another in the lower walls. These inlets may, if desired, be offset from one another; for example in a tangential arrangement.
The closure means preferably comprises a mouthpiece. That is to say, the closure means is preferably such that it includes means by or via which medicament may be inhaled from the device by the user. An inhaler mouthpiece is preferably pivotably attached to the housing.
The air outlet of the medicament chamber is suitably positioned so as to connect or coincide with the mouthpiece in its fully closed position. For example, the mouthpiece may suitably comprise means to receive air from an outlet of the medicament chamber, such that when the mouthpiece is closed the means for receiving air is connected with, or cooperates with, the outlet. Suitably, the means (e.g. a tube which may be cylindrical or oval shaped in cross section) comprises one end which connects with the outlet of the medicament chamber, and another end which comprises an outlet for the medicament, from which outlet medicament is inhaled by the user. It is preferred that the end which connects with the outlet of the medicament chamber comprises the vents, preferably two opposing crescent-shaped vents positioned at either side. The arrangement is preferably such that the vents are in close proximity to the outlet of the medicament chamber. The outlet of the said means may constitute the final air outlet of the inhaler device. Preferably, the positioning, in particular the angle, of the vents is such that in use the direction of airflow through the vents is in the same general direction as the direction of the main inhalation airflow through the inhalation passage. As described above, the vents are typically formed as a hole or opening through the thickness of one or more walls of the inhalation passage. Where the wall thickness is such that an axis through the vent can be defined, the axis of the vent is preferably at an angle of less than 90 degrees, more preferably 45 degrees or less, relative to the direction of the main inhalation airflow through the inhalation passage. That is to say, the flow of air through the vents into the inhalation passage is preferably not perpendicular to, or against, the main inhalation flow, but flows in the same general direction.
The Revolizer™ inhalation device comprises a holder for a medicament, which holder comprises a chamber suitable for receiving a medicament capsule; and means for generating turbulence in a fluid flow through the chamber such that, in use, the turbulent fluid flow causes vibration of a capsule received by the chamber so as to assist in releasing medicament contained within the capsule. Maximizing the turbulence in the chamber enhances drug dispersion and delivery.
The means for generating turbulence preferably also holds, or partially holds, a medicament capsule within the holder. Optionally, the means for generating turbulence holds one end of a medicament capsule. Preferably the capsule is held loosely (either completely, partially or at one end), which means that any significant movement of the capsule is prevented but the capsule is still enabled to make small vibratory movements within the chamber.
The means for generating turbulence may be any suitable means but preferably comprises one or more projections or flow barriers extending from the inner walls of the chamber. Preferably, the means for generating turbulence extend substantially the entire length of the chamber - that is, substantially from top to bottom. Increasing the height of the means for generating turbulence results in reduced retention of medicament in the chamber, and also reduced leakage of medicament from around the top of the chamber.
According to another embodiment of the present invention, the pharmaceutical composition of the present invention may be administered by a metered dose inhaler (MDI). The metered dose inhalers, according to the present invention, may comprise one or more pharmaceutically acceptable excipients such as hydrofluoroalkane (HFC/HFA) propellants, co-solvents, bulking agents, non volatile component, buffers/pH adjusting agents, surface active agents, preservatives, complexing agents, or combinations thereof.
Propellants are those which, when mixed with the cosolvent(s), form a homogeneous propellant system in which a therapeutically effective amount of the active can be dissolved. The hydrofluoroalkane HFC/HFA propellant must be toxicologically safe and must have a vapor pressure which is suitable to enable the medicament to be administered via a pressurized MDI.
According to the present invention, the HFC/HFA propellants may comprise, but are not limited to, one or more of 1,1, 1,2-tetrafluoroethane (HFC-134(a)) and 1,1,1,2,3,3,3,- heptafluoropropane (HFC-227), HFC-32 (difluoromethane), HFC-143(a) (1,1,1-trifluoroethane), HFC-134 (1,1,2,2-tetrafluoroethane), and HFC-152a (1,1- difluoroethane) and such other propellants which may be known to the person a skilled in the art.
Co-solvent is any solvent which may be volatile or non-volatile, which is miscible in the formulation in the amount desired and which, when added provides a formulation in which the medicament can be dissolved or suspended. The function of the cosolvent is to increase the solubility of the medicament and the excipients in the formulation.
According to the present invention, the volatile and non-volatile co-solvent may comprise one or more of, C2-C6 aliphatic alcohols, such as but not limited to, ethyl alcohol and isopropyl alcohol; glycols such as but not limited to, propylene glycol, polyethylene glycols, polypropylene glycols, glycol ethers, and block copolymers of oxyethylene and oxypropylene; and other substances, such as but not limited to, polyoxyethylene alcohols, and polyoxyethylene fatty acid esters; hydrocarbons such as but not limited to, n-propane, n-butane, isobutane, n-pentane, iso-pentane, neo-pentane, and n-hexane; and ethers such as but not limited to, diethyl ether, monosaccharides such as but not limited to, glucose, arabinose; disaccharides such as lactose, maltose; oligosaccharides and polysaccharides such as but not limited to, dextrans; polyalcohol such as but not limited to, glycerol, sorbitol, mannitol, xylitol; salts such as but not limited to, potassium chloride, magnesium chloride, magnesium sulphate, sodium chloride, sodium citrate, sodium phosphate, sodium hydrogen phosphate, sodium hydrogen carbonate, potassium citrate, potassium phosphate, potassium hydrogen phosphate, potassium hydrogen carbonate, calcium carbonate and calcium chloride.
Suitable buffers or pH adjusting agents may be employed in the MDI formulation of the present invention.
According to the present invention, the buffer or the pH adjusting agent may comprise one or more of organic or inorganic acids such as but not limited to, citric acid, ascorbic acid, hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid.
Suitable preservatives may be employed in the MDI formulation of the present invention to protect the formulation from contamination with pathogenic bacteria.
According to the present invention, the preservative may comprise, but not limited to, one or more of benzalkonium chloride, benzoic acid, benzoates such as sodium benzoate and such other preservatives which may be known to the person skilled in the art.
Suitable complexing agents may also be employed in the MDI formulation of the present invention which are capable of forming complex bonds.
According to the present invention, the complexing agent may comprise one or more of, but not limited to sodium EDTA or disodium EDTA.
Suitable surfactants may also be employed in the MDI formulation of the present invention which serve to stabilize the solution formulation and improve the performance of valve systems of the metered dose inhaler. According to the present invention, the surfactant may comprise one or more ionic and/or non-ionic surfactant, but not limited to, oleic acid, sorbitan trioleate, lecithin, isopropylmyristate, tyloxapol, polysorbates such as polysorbate 80, vitamin E-TPGS, and macrogol hydroxystearates such as macrogol-15-hydroxystearate.
Optionally, the powder for inhalation intended to be used for DPI may be suspended in a suitable vehicle and packaged in a container along with suitable propellants or mixtures thereof to form a composition suitable for administration by MDI.
Suitable vehicles which may be used in the pharmaceutical composition of the invention may comprise, but are not limited to, polar solvents, such as compounds that contain hydroxyl groups or other polar groups. Such solvents may include water or alcohols, such as ethanol, isopropanol, and glycols including propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol and polyoxyethylene alcohols.
According to a further embodiment, the pharmaceutical composition of the present invention may be administered by nebulization.
The pharmaceutical composition to be administered by a nebulizer, according to the present invention may comprise suitable excipients such as, but not limited to, tonicity agents, surfactants or wetting agents, buffers/pH regulators, chelating agents in a suitable vehicle such as water.
Suitable surfactants or wetting agents may also be used in the pharmaceutical compositions of the present invention. According to the present invention, the surfactants may comprise one or more of, but not limited to polysorbates such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polysorbate 65, polysorbate 85, sorbitan. fatty acid esters such as Span 20, Span 40, Span 60, Span 80, Span 120; sodium lauryl sulfate; polyethoxylated castor oil; polyethoxylated hydrogenated castor oil, sodium dodecyl sulfate (sodium lauryl sulfate), lauryl dimethyl amine oxide, docusate sodium, cetyl trimethyl ammonium bromide (CTAB), polyethoxylated alcohols, polyoxyethylene sorbitan, octoxynol, N, N-dimethyldodecylamine-N-oxide, Hexadecyltrimethyl- ammonium bromide, polyoxyl 10 lauryl ether, Brij, bile salts (sodium deoxycholate, sodium cholate), polyoxyl castor oil, nonylphenol ethoxylate, cyclodextrins, lecithin, methylbenzethonium chloride, carboxylates, sulphonates, petroleum sulphonates, alkylbenzenesulphonates, naphthalenesulphonates, olefin sulphonates, alkyl sulphates, sulphates, sulphated natural oils and fats, sulphated esters, sulphated alkanolamides, alkylphenols, ethoxylated and sulphated, ethoxylated aliphatic alcohol, polyoxyethylene surfactants, carboxylic esters, polyethylene glycol esters, anhydrosorbitol ester and its ethoxylated derivatives, glycol esters of fatty acids, carboxylic amides, monoalkanolamine condensates, polyoxyethylene fatty acid amides, quaternary ammonium salts, amines with amide linkages, polyoxyethylene alkyl and alicyclic amines, Ν,Ν,Ν,Ν tetrakis substituted ethylenediamines, 2-alkyl 1-hydroxyethyl 2-imidazolines, N-coco 3-aminopropionic acid / sodium salt, N-tallow 3-imino- dipropionate disodium salt, N-carboxymethyl n-dimethyl n-9-octadecenyl ammonium hydroxide and n-cocoamidethyl n-hydroxyethylglycine sodium salt.
Tonicity-adjusting agents, which may be used, comprise, but are not limited to, sodium chloride, potassium chloride, zinc chloride, calcium chloride and mixtures thereof. Other isotonicity-adjusting agents may also include, but are not limited to, mannitol, glycerol, and dextrose and mixtures thereof.
The pH may be adjusted by the addition of pharmacologically acceptable acids. Pharmacologically acceptable inorganic acids or organic acids may be used for this purpose. Examples of preferred inorganic acids are selected from the group consisting of hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and phosphoric acid. Examples of particularly suitable organic acids are selected from the group consisting of ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and propionic acid. Complexing agents according to the present invention may comprise, but are not limited to, editic acid (EDTA) or one of the known salts thereof, e.g. sodium EDTA or disodium EDTA dihydrate (sodium edetate).
An anti-microbial preservative agent may be added for multi-dose packages.
Suitably, the pharmaceutical composition according to the present invention is administered using dosage forms suitable for delivery of drugs to the respiratory tract. However, other dosage forms such as parentral dosage forms may also be envisaged under the ambit of the invention.
The present invention also provides a process to manufacture compositions according to the present invention.
The present invention provides a process of preparing a dry powder inhalation formulation which process comprises admixing of a pharmaceutically acceptable carrier or excipient with the actives and providing the formulation as a dry powder inhaler.
The present invention further provides a method for treatment and/or prophylaxis of influenza which comprises administering a pharmaceutical composition according to the present invention comprising a low dose of zanamivir.
It may be well acknowledged to a person skilled in the art that the said pharmaceutical composition, according to the present invention, may further comprise one or more active in particular antibiotics, anti-bacterial and other anti-viral agents such as those used to treat respiratory infections.
For example, other compounds effective against influenza viruses, such as but not limited to, amantadine, rimantadine, acyclovir, azidothymidine, vidarabine, ribavirin, dapsone, chloramphenicol, neomycin, cefaclor, cefadroxil, cephalexin, erythromycin, clindamycin, lincomycin, amoxicillin, ampicillin, carbenicillin, methicillin, nafcillin, penicillin, polymyxin, tetracycline, amphotericin-b, candicidin, lucensomycin, mepartricin, natamycin, nystatin, griseofulvin, oligomycins, neomycin tubercidin, picloxacillin, penicllins, sulfonamides, cephalosporins, quinolones, or their pharmaceutically acceptable salts, solvates, tautomers, derivatives, enantiomers, isomers, hydrates, prodrugs or polymorphs thereof may be included in such combinations.
The following examples are for the purpose of illustration of the invention only and are not intended in any way to limit the scope of the present invention.
Example 1
Figure imgf000017_0001
Process:
1) Zanamivir was sifted with fine lactose.
2) The mixture obtained in step (1) was co-sifted with coarse lactose.
3) The mixture obtained in step (2) was blended and filled into capsules.
Example 2
Sr. No. Ingredients Qty/Unit
(mg/capsule)
1. Zanamivir 4.00
2. Coarse Lactose 14.70
3. Fine Lactose 6.30
Total 25.00 Process:
1) Zanamivir was sifted with fine lactose.
2) The mixture obtained in step (1) was co-sifted with coarse lactose.
3) The mixture obtained in step (2) was blended and filled into capsules.
To illustrate the Revolizer™ inhalation device, a preferred embodiment thereof will now be described with reference to the accompanying drawings (which in no way restrict the scope of the invention and are for the purpose of illustration only) in which:
Figure 1 is a cross-sectional view of the inhalation device, with piercing means in a fully retracted position and the inhaler mouthpiece in a fully opened position.
Figure 2 is a cross-sectional view of the inhalation device, with piercing means in a fully extended piercing position and the inhaler mouthpiece in a partially open/partially closed position, and illustrates a preferred position of the vents.
Figure 3 is a cross-sectional view of the inhalation device, with piercing means in a fully retracted position and the inhaler mouthpiece in a fully closed position.
Figure 4 is a perspective view of the exterior of the inhalation device with the mouthpiece in the fully closed position.
Figure 5 is a plan view of a side of the inhalation device with the mouthpiece in the fully closed position.
Figure 6 is a plan view of the other side (with respect to Figure 5) of the inhalation device with the mouthpiece in the fully closed position.
Figure 7 is a plan view of the rear of the inhalation device with the mouthpiece in the fully closed position.
Figure 8 is a plan view of the front of the inhalation device with the mouthpiece in the fully closed position.
Figure 9 is a top end view of the inhalation device with the mouthpiece in the fully closed position, viewed from the mouthpiece end.
Figure 10 is a bottom end view of the inhalation device with the mouthpiece in the fully closed position, viewed from the lower body end.
Figure 11 is a perspective view of a holder for a dry powder medicament capsule. Figure 12 is an end view of the medicament capsule holder, viewed from the air outlet end.
Figure 13 is an end view of the medicament capsule holder viewed from the air inlet end.
Figure 14 is a front view of the medicament capsule holder.
Figure 15 is a side view of the medicament capsule holder.
Figure 16 is a rear view of the medicament capsule holder.
Figure 17 is a side view of the medicament capsule holder.
Figure 18 is a top end view of a preferred inhalation device with the mouthpiece in the fully closed position, viewed from the mouthpiece end. It illustrates the position of the vents.
Figure 19 is a cross-section of a preferred inhalation device illustrating projections ( 16) of increased height compared to Figure 11.
Figure 20 is a cross-section of a preferred inhalation device and shows a preferred position of the vents.
The Revolizer™ inhalation device comprises a lower body (1) having a medicament or capsule holder (2) to hold the capsule or similar suitable medicament receptacle, and a mouthpiece (3) attached to the lower body (1) by a pivot (30) about which the mouthpiece (3) is rotatable.
The medicament or capsule holder (2) comprises a chamber (14) to receive a capsule, an air inlet (1 1), an air outlet (12), and means for generating turbulence (16). The means for generating turbulence (16) may comprise one or more projection(s), as shown in Figures 1 1 and 12. Preferably, the projections (16) extend to substantially the top of medicament chamber (14) so that they align with the upper rim of the chamber (14), as illustrated in Figure 19.
The means for generating turbulence (16) have a dual function: they both hold a capsule (10) received within the chamber (14), and generate turbulence in fluid flow through the chamber (14) and around a capsule (10) received therein. The capsule holder (2) is preferably adapted to receive one or more piercing pins (7) that are moveable between a retracted position in a piercing pin holder (6), shown in Figures 1 and 3, and an extended piercing position, shown in Figure 2. The piercing pins (7) are operated by a link (5) that enables the linear movement of the piercing pin (7) to pierce the capsule or similar suitable medicament receptacle (10) and retract back.
In one embodiment, guide means (20) extend from the openings (18) in a side wall of the chamber (2). The guide means (20) are positioned so as to guide the movement of the piercing pins (7) between fully extended and fully retracted positions. The guide means (20) can be best appreciated from Figures 11 to 17.
The mouthpiece (3) pivots laterally to the lower body (1) so as to rotate about an axis and thereby open and close the outlet (12) of the capsule holder (2).
Figure 2 illustrates the preferred position of the vents (70, the vents themselves are not shown in the drawing). Two crescent-shaped vents are positioned opposing each other on either side of a mesh (9). Figure 2 also illustrates the primary air inlet (71) on the base of the lower body or housing (1), and the final air outlet (72) on mouthpiece (3). When the device is in the closed position (as in Figure 3), the device defines an inhalation passage extending through the device between inlet (71) and outlet (72). Figure 18 illustrates a preferred position of the vents (70) relative to mesh (9). The exact positioning can be appreciated with reference to Figure 20, which shows the position of vents (70) relative to the mouthpiece (3) and lower body (1).
In use, the mouthpiece (3) is opened, thereby retracting the piercing pins (7), and a capsule or similar suitable medicament receptacle (10) is placed into the chamber (14). The projections (16) loosely hold the capsule (10) within the chamber (14). On closing the mouthpiece (3), the piercing pins (7) pierce the capsule (10) in the capsule holder (2) as shown in Figure 2. On fully closing the mouthpiece (3), the piercing pins retract from the medicament holder (2). As air is inhaled by the user from the chamber (14) through the outlet (12) and mouthpiece (3), the projections (16) generate turbulence in the air flow through the chamber (14). Turbulence in the air flowing around the capsule (10) causes vibration of the capsule (10) within the chamber (14), and this vibration enhances the dispersion of medicament contained within the capsule (10). Accordingly, less forceful inhalation by the user is required to liberate a full dose of medicament from the capsule (10).
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein. Thus, it should be understood that although the present invention has been specifically disclosed by the preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and such modifications and variations are considered to be falling within the scope of the invention.
It is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of "including," "comprising," or "having" and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.
It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "an excipient" includes a single excipient as well as two or more different excipients, and the like.

Claims

Claims
1. A pharmaceutical composition comprising zanamivir and one or more pharmaceutically acceptable excipients, wherein the total daily dose of the zanamivir is less than 10 mg.
2. A pharmaceutical composition according to claim 1, for administration at least once a day.
3. A pharmaceutical composition according to claim 1 or 2, wherein the composition delivers from 3 mg to 8 mg of zanamivir per administered dose.
4. A pharmaceutical composition according to claim 1, 2 or 3, formulated for use as a dry powder inhaler (DPI), metered dose inhaler (MDI), nebuliser, nasal spray, nasal drops or insufflation powders.
5. A pharmaceutical composition according to claim 4 formulated for use as a dry powder inhalation formulation.
6. A pharmaceutical composition according to claim 5, further comprising at least one finely divided pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulations.
7. A combination composition according to claim 6, wherein said carrier includes a saccharide and/or a sugar alcohol.
8. A pharmaceutical composition according to claim 5, 6 or 7, wherein the pharmaceutical composition is encapsulated in capsules, or is encapsulated in blisters, or is contained within a reservoir in a single-dose or multi-dose dry powder inhalation device.
9. A pharmaceutical composition according to any one of claims 5 to 8, wherein the pharmaceutical composition is administered via Revolizer™.
10. A pharmaceutical composition according to any one of the preceding claims further comprising one or more active(s) selected from amantadine, rimantadine, acyclovir, azidothymidine, vidarabine, ribavirin, dapsone, chloramphenicol, neomycin, cefaclor, cefadroxil, cephalexin, erythromycin, clindamycin, lincomycin, amoxicillin, ampicillin, carbenicillin, methicillin, nafcillin, penicillin, polymyxin, tetracycline, amphotericin-b, candicidin, lucensomycin, mepartricin, natamycin, nystatin, griseofulvin, oligomycins, neomycin tubercidin, picloxacillin, penicllins, sulfonamides, cephalosporins or quinolones or their pharmaceutically acceptable salts, solvates, tautomers, derivatives, enantiomers, isomers, hydrates, prodrugs or polymorphs thereof.
11. A process for preparing a pharmaceutical composition for administration according to any one of the preceding claims, which process comprises admixing one or more pharmaceutically acceptable excipients with zanamivir.
12. Use of a pharmaceutical composition according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment and/or prophylaxis of viral diseases.
13. Use of a pharmaceutical composition according to claim 12 in the manufacture of a medicament for the treatment and/or prophylaxis of viral diseases caused by influenza A and B, parainfluenza, mumps, and Newcastle disease, fowl plaque and Sendai virus.
14. A method of treatment and/or prophylaxis of viral diseases comprising administering a therapeutically effective amount of a composition according to any one of claims 1 to 10 to a patient in need thereof.
15. A pharmaceutical composition substantially as herein described with reference to the examples.
PCT/GB2011/001395 2010-09-27 2011-09-26 Low dose pharmaceutical composition Ceased WO2012042197A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP11767280.8A EP2621485A2 (en) 2010-09-27 2011-09-26 Low dose pharmaceutical composition comprising zanamivir
US13/825,469 US20130251790A1 (en) 2010-09-27 2011-09-26 Low Dose Pharmaceutical Composition Comprising Zanamivir
MX2013003523A MX2013003523A (en) 2010-09-27 2011-09-26 Low dose pharmaceutical composition comprising zanamivir.
BR112013006857A BR112013006857A2 (en) 2010-09-27 2011-09-26 pharmaceutical composition, process for preparing a pharmaceutical composition, use of a pharmaceutical composition and method for the treatment or prophylaxis of viral diseases
CN2011800464443A CN103260615A (en) 2010-09-27 2011-09-26 Low dose pharmaceutical composition
RU2013119595/15A RU2013119595A (en) 2010-09-27 2011-09-26 LOW-DOSE PHARMACEUTICAL COMPOSITION
AU2011309944A AU2011309944A1 (en) 2010-09-27 2011-09-26 Low dose pharmaceutical composition comprising zanamivir
ZA2013/02012A ZA201302012B (en) 2010-09-27 2013-03-18 Low dose pharmaceutical composition
US14/504,051 US20150034087A1 (en) 2010-09-27 2014-10-01 Low Dose Pharmaceutical Composition Comprising Zanamivir

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2684MU2010 2010-09-27
IN2684/MUM/2010 2010-09-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/825,469 A-371-Of-International US20130251790A1 (en) 2010-09-27 2011-09-26 Low Dose Pharmaceutical Composition Comprising Zanamivir
US14/504,051 Division US20150034087A1 (en) 2010-09-27 2014-10-01 Low Dose Pharmaceutical Composition Comprising Zanamivir

Publications (2)

Publication Number Publication Date
WO2012042197A2 true WO2012042197A2 (en) 2012-04-05
WO2012042197A3 WO2012042197A3 (en) 2012-08-02

Family

ID=44773097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/001395 Ceased WO2012042197A2 (en) 2010-09-27 2011-09-26 Low dose pharmaceutical composition

Country Status (9)

Country Link
US (2) US20130251790A1 (en)
EP (1) EP2621485A2 (en)
CN (1) CN103260615A (en)
AU (1) AU2011309944A1 (en)
BR (1) BR112013006857A2 (en)
MX (1) MX2013003523A (en)
RU (1) RU2013119595A (en)
WO (1) WO2012042197A2 (en)
ZA (1) ZA201302012B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170326102A1 (en) * 2014-11-27 2017-11-16 Cipla Limited Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery
CA3016119A1 (en) * 2016-03-01 2017-09-08 Emerging Viral Therapeutics (HK) Limited Compositions and methods for treatment of influenza virus
CN109953977A (en) * 2017-12-25 2019-07-02 深圳市华力康生物医药有限公司 A kind of nasal inhalation powder formulation and its device
SG11202103776YA (en) * 2018-12-03 2021-05-28 Sirtex Medical Inc Apparatus for delivery of radioembolization microspheres
CN110101653A (en) * 2019-04-19 2019-08-09 珐玛赫(天津)医药科技有限公司 A kind of nasal cavity situ-gel composition, Its Preparation Method And Use
GB202001906D0 (en) * 2020-02-12 2020-03-25 Nasaleze Patents Ltd Compositions And Applications Thereof
CA3126367A1 (en) 2020-03-30 2021-09-30 Pulmonem Inc. Dapsone formulations and methods of using same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0764023A1 (en) 1994-05-28 1997-03-26 Biota Scientific Management Pty. Ltd. Compounds and compositions for administration via oral inhalation or insufflation
JP2002241310A (en) 2001-02-21 2002-08-28 Taisho Pharmaceut Co Ltd Topical composition
WO2006051300A1 (en) 2004-11-10 2006-05-18 Cipla Limited Inhaler
WO2007144659A1 (en) 2006-06-16 2007-12-21 Cipla Limited Improved dry powder inhaler
CN101229122A (en) 2008-02-02 2008-07-30 中国科学院上海药物研究所 Zanamivir nasal in-situ gel with phase transition properties and preparation method thereof
CN101773491A (en) 2010-03-23 2010-07-14 江苏先声药物研究有限公司 Zanamivir inhalation solution and application thereof
CN101773468A (en) 2009-01-08 2010-07-14 中国科学院上海药物研究所 Zanamivir nasal nanometer suspension and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001224A2 (en) * 2007-06-22 2008-12-31 Eth Zurich Antivirals

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0764023A1 (en) 1994-05-28 1997-03-26 Biota Scientific Management Pty. Ltd. Compounds and compositions for administration via oral inhalation or insufflation
JP2002241310A (en) 2001-02-21 2002-08-28 Taisho Pharmaceut Co Ltd Topical composition
WO2006051300A1 (en) 2004-11-10 2006-05-18 Cipla Limited Inhaler
WO2007144659A1 (en) 2006-06-16 2007-12-21 Cipla Limited Improved dry powder inhaler
CN101229122A (en) 2008-02-02 2008-07-30 中国科学院上海药物研究所 Zanamivir nasal in-situ gel with phase transition properties and preparation method thereof
CN101773468A (en) 2009-01-08 2010-07-14 中国科学院上海药物研究所 Zanamivir nasal nanometer suspension and preparation method thereof
CN101773491A (en) 2010-03-23 2010-07-14 江苏先声药物研究有限公司 Zanamivir inhalation solution and application thereof

Also Published As

Publication number Publication date
US20150034087A1 (en) 2015-02-05
RU2013119595A (en) 2014-11-10
US20130251790A1 (en) 2013-09-26
EP2621485A2 (en) 2013-08-07
MX2013003523A (en) 2013-05-22
WO2012042197A3 (en) 2012-08-02
CN103260615A (en) 2013-08-21
AU2011309944A1 (en) 2013-04-04
BR112013006857A2 (en) 2016-06-14
ZA201302012B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
US20150034087A1 (en) Low Dose Pharmaceutical Composition Comprising Zanamivir
JP6664358B2 (en) Stable fixed dose pharmaceutical composition having mometasone and olopatadine
ES2671342T3 (en) Nebulized antibiotics for inhalation therapy
ES2745064T3 (en) Super fine formoterol formulation
ES2332290T3 (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE A BETA2 AGONIST OF LONG-TERM ACTION FOR ADMINISTRATION THROUGH NEBULIZATION.
EP2259773B1 (en) Macrolide compositions having improved taste and stability
US20090298802A1 (en) Pharmaceutical Compositions
WO2008025560A1 (en) Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
KR102733397B1 (en) Intranasal epinephrine formulations and methods for the treatment of disease
CN101795565A (en) Nasal and ocular administration of aqueous corticosteroid solutions
TR201820559T4 (en) Compositions containing Azelastine and methods of use.
WO2021229514A1 (en) Pharmaceutical ivermectin compositions
US20180000843A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US20170326102A1 (en) Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery
JP2024502990A (en) Inhalable imatinib formulation
ES2612257T3 (en) Improved suspension formulation of beclomethasone dipropionate for administration by inhalation
TW201717936A (en) Sprayer composition
HK40121592A (en) Intranasal epinephrine formulations and methods for the treatment of disease
TW202529757A (en) Intranasal formulations for treating obstructive sleep apnea
EA052369B1 (en) EPINEPHRINE-BASED INTRANASALS AND METHODS OF TREATMENT
HK1118473A (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11767280

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2011767280

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011767280

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/003523

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011309944

Country of ref document: AU

Date of ref document: 20110926

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013119595

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13825469

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013006857

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013006857

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130325